[Federal Register: June 20, 2007 (Volume 72, Number 118)]
[Notices]               
[Page 34041]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20jn07-135]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated February 5, 2007, and published in the Federal 
Register on February 12, 2007, (72 FR 6579), Orasure Technologies, 
Inc., Lehigh University, Seeley G. Mudd-Building 6, 220 East First 
Street, Bethlehem, Pennsylvania 18015, made application by renewal to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (LSD) (7315)....  I
4-Methoxyamphetamine (7411)................  I
Normorphine (9313).........................  I
Tetrahydrocannabinols (THC) (7370).........  I
Alphamethadol (9605).......................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Cocaine (9041).............................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Oxycodone (9143)...........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk to manufacture controlled substance derivatives. These 
derivatives will be used in diagnostic products created specifically 
for internal use only.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Orasure Technologies, Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Orasure Technologies, Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

     Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-11907 Filed 6-19-07; 8:45 am]

BILLING CODE 4410-09-P